Cargando…
CD82 protects against glaucomatous axonal transport deficits via mTORC1 activation in mice
Glaucoma is a leading cause of irreversible blindness worldwide and is characterized by progressive optic nerve degeneration and retinal ganglion cell loss. Axonal transport deficits have been demonstrated to be the earliest crucial pathophysiological changes underlying axonal degeneration in glauco...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665930/ https://www.ncbi.nlm.nih.gov/pubmed/34897284 http://dx.doi.org/10.1038/s41419-021-04445-6 |
_version_ | 1784614110504157184 |
---|---|
author | Ye, Meng Huang, Jingqiu Mou, Qianxue Luo, Jing Hu, Yuanyuan Lou, Xiaotong Yao, Ke Zhao, Bowen Duan, Qiming Li, Xing Zhang, Hong Zhao, Yin |
author_facet | Ye, Meng Huang, Jingqiu Mou, Qianxue Luo, Jing Hu, Yuanyuan Lou, Xiaotong Yao, Ke Zhao, Bowen Duan, Qiming Li, Xing Zhang, Hong Zhao, Yin |
author_sort | Ye, Meng |
collection | PubMed |
description | Glaucoma is a leading cause of irreversible blindness worldwide and is characterized by progressive optic nerve degeneration and retinal ganglion cell loss. Axonal transport deficits have been demonstrated to be the earliest crucial pathophysiological changes underlying axonal degeneration in glaucoma. Here, we explored the role of the tetraspanin superfamily member CD82 in an acute ocular hypertension model. We found a transient downregulation of CD82 after acute IOP elevation, with parallel emergence of axonal transport deficits. The overexpression of CD82 with an AAV2/9 vector in the mouse retina improved optic nerve axonal transport and ameliorated subsequent axon degeneration. Moreover, the CD82 overexpression stimulated optic nerve regeneration and restored vision in a mouse optic nerve crush model. CD82 exerted a protective effect through the upregulation of TRAF2, which is an E3 ubiquitin ligase, and activated mTORC1 through K63-linked ubiquitylation and intracellular repositioning of Raptor. Therefore, our study offers deeper insight into the tetraspanin superfamily and demonstrates a potential neuroprotective strategy in glaucoma treatment. |
format | Online Article Text |
id | pubmed-8665930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-86659302021-12-27 CD82 protects against glaucomatous axonal transport deficits via mTORC1 activation in mice Ye, Meng Huang, Jingqiu Mou, Qianxue Luo, Jing Hu, Yuanyuan Lou, Xiaotong Yao, Ke Zhao, Bowen Duan, Qiming Li, Xing Zhang, Hong Zhao, Yin Cell Death Dis Article Glaucoma is a leading cause of irreversible blindness worldwide and is characterized by progressive optic nerve degeneration and retinal ganglion cell loss. Axonal transport deficits have been demonstrated to be the earliest crucial pathophysiological changes underlying axonal degeneration in glaucoma. Here, we explored the role of the tetraspanin superfamily member CD82 in an acute ocular hypertension model. We found a transient downregulation of CD82 after acute IOP elevation, with parallel emergence of axonal transport deficits. The overexpression of CD82 with an AAV2/9 vector in the mouse retina improved optic nerve axonal transport and ameliorated subsequent axon degeneration. Moreover, the CD82 overexpression stimulated optic nerve regeneration and restored vision in a mouse optic nerve crush model. CD82 exerted a protective effect through the upregulation of TRAF2, which is an E3 ubiquitin ligase, and activated mTORC1 through K63-linked ubiquitylation and intracellular repositioning of Raptor. Therefore, our study offers deeper insight into the tetraspanin superfamily and demonstrates a potential neuroprotective strategy in glaucoma treatment. Nature Publishing Group UK 2021-12-11 /pmc/articles/PMC8665930/ /pubmed/34897284 http://dx.doi.org/10.1038/s41419-021-04445-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Ye, Meng Huang, Jingqiu Mou, Qianxue Luo, Jing Hu, Yuanyuan Lou, Xiaotong Yao, Ke Zhao, Bowen Duan, Qiming Li, Xing Zhang, Hong Zhao, Yin CD82 protects against glaucomatous axonal transport deficits via mTORC1 activation in mice |
title | CD82 protects against glaucomatous axonal transport deficits via mTORC1 activation in mice |
title_full | CD82 protects against glaucomatous axonal transport deficits via mTORC1 activation in mice |
title_fullStr | CD82 protects against glaucomatous axonal transport deficits via mTORC1 activation in mice |
title_full_unstemmed | CD82 protects against glaucomatous axonal transport deficits via mTORC1 activation in mice |
title_short | CD82 protects against glaucomatous axonal transport deficits via mTORC1 activation in mice |
title_sort | cd82 protects against glaucomatous axonal transport deficits via mtorc1 activation in mice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665930/ https://www.ncbi.nlm.nih.gov/pubmed/34897284 http://dx.doi.org/10.1038/s41419-021-04445-6 |
work_keys_str_mv | AT yemeng cd82protectsagainstglaucomatousaxonaltransportdeficitsviamtorc1activationinmice AT huangjingqiu cd82protectsagainstglaucomatousaxonaltransportdeficitsviamtorc1activationinmice AT mouqianxue cd82protectsagainstglaucomatousaxonaltransportdeficitsviamtorc1activationinmice AT luojing cd82protectsagainstglaucomatousaxonaltransportdeficitsviamtorc1activationinmice AT huyuanyuan cd82protectsagainstglaucomatousaxonaltransportdeficitsviamtorc1activationinmice AT louxiaotong cd82protectsagainstglaucomatousaxonaltransportdeficitsviamtorc1activationinmice AT yaoke cd82protectsagainstglaucomatousaxonaltransportdeficitsviamtorc1activationinmice AT zhaobowen cd82protectsagainstglaucomatousaxonaltransportdeficitsviamtorc1activationinmice AT duanqiming cd82protectsagainstglaucomatousaxonaltransportdeficitsviamtorc1activationinmice AT lixing cd82protectsagainstglaucomatousaxonaltransportdeficitsviamtorc1activationinmice AT zhanghong cd82protectsagainstglaucomatousaxonaltransportdeficitsviamtorc1activationinmice AT zhaoyin cd82protectsagainstglaucomatousaxonaltransportdeficitsviamtorc1activationinmice |